Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1987 1
1993 1
1996 2
1997 1
1998 3
2000 1
2006 4
2007 1
2009 2
2010 2
2011 2
2012 4
2013 1
2015 1
2016 1
2017 1
2018 1
2019 2
2020 2
2021 1
2022 2
2023 1
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Morris K, Pompilus F, Phillips-Jones A, Zhou XL, Fulci G, Sule N, Kremer BE, Opalinska J, Mateos MV, Trudel S; DREAMM-8 Investigators. Dimopoulos MA, et al. N Engl J Med. 2024 Aug 1;391(5):408-421. doi: 10.1056/NEJMoa2403407. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828951 Clinical Trial.
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.
Thoms JAI, Yan F, Hampton HR, Davidson S, Joshi S, Saw J, Sarowar CH, Lim XY, Nunez AC, Kakadia PM, Bhuyan GS, Zou X, Nguyen M, Ghodousi ES, Koch FC, Vafaee F, Thompson IR, Karimi MM, Pickford R, Raftery MJ, Hough S, Buckland G, Bailey M, Ghodke Y, Absar N, Vaughan L, Pasalic L, Fong CY, Kenealy M, Hiwase DK, Stoddart RI, Mohammed S, Lee L, Passam FH, Larsen SR, Spring KJ, Skarratt KK, Rebeiro P, Presgrave P, Stevenson WS, Ling S, Tiley C, Fuller SJ, Roncolato F, Enjeti AK, Hoenemann D, Lemech C, Jolly CJ, Bohlander SK, Curtis DJ, Wong JWH, Unnikrishnan A, Hertzberg M, Olivier J, Polizzotto MN, Pimanda JE. Thoms JAI, et al. Among authors: kenealy m. Nat Commun. 2025 May 13;16(1):4451. doi: 10.1038/s41467-025-59796-x. Nat Commun. 2025. PMID: 40360497 Free PMC article. Clinical Trial.
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Wilkes J, McNamara S, Phillips-Jones A, Morris K, Pompilus F, Purser M, Sule N, Kremer B, Loubert A, Bunod L, M'Hari M, Zhou XL, Fulci G, Mateos MV, Trudel S; DREAMM-8 investigators. Dimopoulos MA, et al. Lancet Haematol. 2025 Nov;12(11):e876-e886. doi: 10.1016/S2352-3026(25)00256-X. Lancet Haematol. 2025. PMID: 41193117 Clinical Trial.
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.
Horvath N, Spencer A, Kenealy M, Joshua D, Campbell PJ, Lee JJ, Hou J, Qiu L, Kalff A, Khong T, Londhe A, Siggins S, van Kooten Losio M, Eisbacher M, Prince HM. Horvath N, et al. Among authors: kenealy m. Leuk Lymphoma. 2019 Sep;60(9):2122-2133. doi: 10.1080/10428194.2019.1579322. Epub 2019 Feb 19. Leuk Lymphoma. 2019. PMID: 30777794 Clinical Trial.
35 results